来自MSN11 分钟
Amgen, AstraZeneca post Phase 3 win for nasal polyps therapy
Citing topline data from their Phase 3 WAYPOINT trial, the companies said that the antibody therapy reduced the size of nasal ...
CBC Online 1380 KCIM42 分钟
FDA seeks to pull common but ineffective OTC cold medicine ingredient off the market
The Food and Drug Administration (“FDA”) said on Thursday that they will seek to pull the common ingredient phenylephrine off ...
来自MSN44 分钟
These Over-The-Counter Decongestants Don't Work, FDA Says
This follows an extensive review that found the drug ineffective for treating nasal congestion. Oral phenylephrine, widely ...
AstraZeneca’s Tezspire Shows Promise in Phase III Trial
AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Tezspire has shown promising results in the Phase III WAYPOINT trial, ...